Inventor · disambiguated record
Kayvan Niazi
Also filed as: NIAZI KAYVAN · NIAZI KAYVAN R
91 granted patents·81 pending applications·165 citations·filing 2005–2025
99Inventor score
Top patents by PatentIndex Score
172 records- 0197US9765330B1Compositions and methods for reduction of allograft recognition and rejectionNANT HOLDINGS IP LLC·Filed 2016·Granted Sep 19, 2017·21 cites·20 claims
- 0295US11421016B2Cancer neoepitopesNANTOMICS LLC·Filed 2016·Granted Aug 23, 2022·16 cites·17 claims
- 0394US10434142B2Compositions and methods of improved wound healingCHAN SOON SHIONG NANTHEALTH FOUND·Filed 2017·Granted Oct 8, 2019·22 cites·14 claims
- 0493US11207392B2Coordinated multi-prong cancer therapyNANT HOLDINGS IP LLC·Filed 2017·Granted Dec 28, 2021·5 cites·15 claims
- 0593US10724043B2Multi-pulse transfection methods and cellsNANTBIO INC·Filed 2017·Granted Jul 28, 2020·21 cites·17 claims
- 0692US11753467B2Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2022·Granted Sep 12, 2023·2 cites·20 claims
- 0792US11298414B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2019·Granted Apr 12, 2022·6 cites·8 claims
- 0891US11071774B2Nant cancer vaccineNANT HOLDINGS IP LLC·Filed 2020·Granted Jul 27, 2021·2 cites·16 claims
- 0991US8633198B1Small molecule inhibitors of influenza A RNA-dependent RNA polymeraseNIAZI KAYVAN·Filed 2012·Granted Jan 21, 2014·15 cites·12 claims
- 1090US11229668B2Maximizing T-cell memory and compositions and methods thereforNANTCELL INC·Filed 2018·Granted Jan 25, 2022·3 cites·20 claims
- 1189US12350323B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2024·Granted Jul 8, 2025·0 cites·18 claims
- 1289US10344280B1Compositions and methods for reduction of allograft recognition and rejectionNANT HOLDINGS IP LLC·Filed 2017·Granted Jul 9, 2019·3 cites·14 claims
- 1388US12329809B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2024·Granted Jun 17, 2025·0 cites·18 claims
- 1488US11756651B2Method of treating a tumor in a patient based on an immune gene expressionNANTOMICS LLC·Filed 2018·Granted Sep 12, 2023·4 cites·5 claims
- 1588US10793875B2Compositions and methods for viral delivery of neoepitopes and uses thereofNANT HOLDINGS IP LLC·Filed 2016·Granted Oct 6, 2020·3 cites·22 claims
- 1688US2025369959A1Live Cell Imaging Systems & Methods of UseNANTBIO INC·Filed 2025·Application pending·0 cites
- 1787US11276479B2Tumor antigenicity processing and presentationNANTOMICS LLC·Filed 2017·Granted Mar 15, 2022·2 cites·8 claims
- 1887US9687491B1Compositions and methods of targeting mutant K-RasRABIZADEH SHAHROOZ·Filed 2012·Granted Jun 27, 2017·6 cites·1 claims
- 1986US11311603B2HIV treatment compositions and methodsNANTCELL INC·Filed 2019·Granted Apr 26, 2022·2 cites·15 claims
- 2086US11154597B2Sequence arrangements and sequences for neoepitope presentationNANTCELL INC·Filed 2017·Granted Oct 26, 2021·2 cites·4 claims
- 2186US11034951B2mRNA display antibody library and methodsNANTBIO INC·Filed 2019·Granted Jun 15, 2021·2 cites·7 claims
- 2285US12303477B2HIV treatment compositions and methodsNANTCELL INC·Filed 2023·Granted May 20, 2025·0 cites·14 claims
- 2385US12285481B2Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid proteinNANTCELL INC·Filed 2023·Granted Apr 29, 2025·0 cites·12 claims
- 2485US9422291B2Small molecule inhibitors of influenza A RNA-dependent RNA polymeraseNANT HOLDINGS IP LLC·Filed 2013·Granted Aug 23, 2016·3 cites·13 claims
- 2585US9315464B1Small molecule inhibitors of influenza A RNA-dependent RNA polymeraseNANT HOLDINGS IP LLC·Filed 2014·Granted Apr 19, 2016·3 cites·7 claims
- 2684US12263189B2Mesenchymal stem cell derived exosomes and methodsNANTBIO INC·Filed 2019·Granted Apr 1, 2025·1 cites·7 claims
- 2784US10752682B2Anti-IL8 antibodiesNANTBIO INC·Filed 2018·Granted Aug 25, 2020·2 cites·10 claims
- 2884US10533157B1Recombinant NK cells expressing co-stimulatory moleculesNANT HOLDINGS IP LLC·Filed 2016·Granted Jan 14, 2020·2 cites·15 claims
- 2984US2024347135A1Difference-based genomic identity scoresNANTOMICS LLC·Filed 2024·Application pending·0 cites
- 3083US11779637B2Targeted neoepitope vectors and methods thereforNANTCELL INC·Filed 2018·Granted Oct 10, 2023·1 cites·10 claims
- 3183US10532089B2Iterative discovery of neoepitopes and adaptive immunotherapy and methods thereforNANTOMICS LLC·Filed 2016·Granted Jan 14, 2020·3 cites·11 claims
- 3282US12416635B2Live cell imaging systems and methods to validate triggering of immune responseNANTBIO INC·Filed 2022·Granted Sep 16, 2025·0 cites·13 claims
- 3382US12112838B2Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2023·Granted Oct 8, 2024·0 cites·20 claims
- 3482US11894109B1Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2019·Granted Feb 6, 2024·2 cites·18 claims
- 3582US2024369565A1Circulating Tumor Cell Enrichment Using NeoepitopesNANT HOLDINGS IP LLC·Filed 2024·Application pending·0 cites
- 3682US2024263355A1mRNA display antibody library and methodsNANTBIO INC·Filed 2024·Application pending·0 cites
- 3781US12397019B2Mesenchymal stem cell derived exosomes and methodsNANTBIO INC·Filed 2024·Granted Aug 26, 2025·0 cites·8 claims
- 3881US12290558B2SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogensIMMUNITYBIO INC·Filed 2023·Granted May 6, 2025·0 cites·11 claims
- 3981US10252269B2Methods of sorting activated T cells using three dimensional dielectrophoresisNANOCAV LLC·Filed 2017·Granted Apr 9, 2019·2 cites·25 claims
- 4081US2023293651A1Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods ThereforNANTOMICS LLC·Filed 2023·Application pending·0 cites
- 4181US2025262288A1Cellular Adjuvants for Viral InfectionNANTBIO INC·Filed 2025·Application pending·0 cites
- 4280US11364265B1Recombinant erIL-15 NK cellsNantCell·Filed 2020·Granted Jun 21, 2022·1 cites·20 claims
- 4380US11361841B2High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapiesNANTOMICS LLC·Filed 2017·Granted Jun 14, 2022·1 cites·12 claims
- 4480US10973852B2NK cells with altered CXCL12/CXCR4 signalingNANT HOLDINGS IP LLC·Filed 2017·Granted Apr 13, 2021·1 cites·15 claims
- 4580US9884087B1Compositions and methods of improved wound healingCHAN SOON SHIONG INST OF ADVANCED HEALTH·Filed 2014·Granted Feb 6, 2018·3 cites·12 claims
- 4680US9750805B2Calcium flux agonists and methods thereforNANT HOLDINGS IP LLC·Filed 2016·Granted Sep 5, 2017·2 cites·20 claims
- 4779US12311018B2Targeted neoepitope vectors and methods thereforNANTCELL INC·Filed 2023·Granted May 27, 2025·0 cites·10 claims
- 4879US12220452B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2022·Granted Feb 11, 2025·0 cites·19 claims
- 4979US12098201B2Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2023·Granted Sep 24, 2024·0 cites·19 claims
- 5079US2024209384A1Multi-Pulse Transfection Methods And CellsNANTBIO INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 172 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kayvan Niazi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →